We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Links Uncovered Between Psychotic Experiences

By LabMedica International staff writers
Posted on 09 Oct 2019
Psychotic experiences, such as hallucinations and delusions, are features of psychiatric disorders, such as schizophrenia, but they are also reported by approximately 5% to 10% of the general population.

Studying the genetic causes of psychotic experiences in the general population, and its association with the genetic causes of other disorders, may increase the understanding of their pathologic significance. More...
There are shared genetic connections between psychotic experiences and conditions on the psychotic spectrum like schizophrenia, but also with conditions like major depressive disorder and autism spectrum disorder.

A team of scientists working with Cardiff University (Cardiff, UK) analyzed data from the UK Biobank to tease out whether the genetic liability for having a psychotic experience overlaps with that of neuropsychiatric diseases. The team included in their analysis individuals diagnosed with a neuropsychiatric condition, and they had a sample of 7,803 individuals who reported experiencing at least one psychotic experience. The 147,461 individuals who reported no such experience served as the control group.

Through a genome-wide association (GWAS) study of any psychotic experience, the scientists identified two variants, an intronic variant in Ankyrin-3 (ANK3) and an intergenic variant rs10994278. ANK3 encodes ankyrin-G, a protein that regulates the assembly of voltage-gated sodium channels and is needed for normal synaptic function. ANK3, the team noted, has also been tied to bipolar disorder. A second GWAS limited to the 2,143 individuals who rated their psychotic experiences to be distressing identified two additional variants, one in an intron of cannabinoid receptor 2 (CNR2) and an intergenic variant rs3849810. CNR2 encodes CB2, one of the two well-known cannabinoid receptors. A third GWAS of the 3,337 individuals who reported multiple psychotic experiences did not turn up any additional loci.

The authors concluded that in the largest GWAS of psychotic experiences from the population-based UK Biobank sample, they found support for a shared genetic liability between psychotic experiences and several psychiatric disorders including schizophrenia, major depressive disorder, bipolar disorder, and neurodevelopmental disorders, indicating that psychotic experiences are not specifically associated with schizophrenia, but rather with a general risk for mental health disorders. The study was published September 25, 2019, in the journal JAMA Psychiatry.

Related Links:
Cardiff University


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.